PMID- 36454278
OWN - NLM
STAT- MEDLINE
DCOM- 20230208
LR  - 20230516
IS  - 2366-0058 (Electronic)
VI  - 48
IP  - 2
DP  - 2023 Feb
TI  - Transarterial embolization of T1b and T2a renal cell carcinoma prior to 
      percutaneous cryoablation: a retrospective comparative study.
PG  - 773-779
LID - 10.1007/s00261-022-03755-3 [doi]
AB  - PURPOSE: To compare outcomes in patients with T1b and T2a renal cell carcinoma 
      (RCC) treated with percutaneous cryoablation (PCA) who underwent transarterial 
      embolization (TAE) of the RCC prior to PCA (TAE + PCA) to patients who were 
      treated with PCA alone. METHODS: Retrospective review of all adult patients with 
      T1b (4.1-7 cm) and T2a (7.1-10 cm) RCC treated with PCA from 2008 to 2021. Data 
      collected included age, sex, tumor diameter, RENAL nephrometry score, technical 
      success, adverse events (AEs), changes in serum creatinine, local control, and 
      recurrence rates. A p value of 0.05 was considered the threshold for statistical 
      significance. RESULTS: 13 patients with 13 RCCs (mean age: 72.7 +/- 10.4; 54% male) 
      and 35 patients with 37 RCCs (mean age: 66.7 +/- 10.6; 60% male) were included in 
      the TAE + PCA and PCA groups, respectively. The TAE + PCA group had larger mean 
      tumor diameter (5.7 +/- 1.1 cm vs. 4.7 +/- 0.6 cm; p < 0.0001) and higher mean RENAL 
      nephrometry score (8.9 +/- 1.1 vs. 7.8 +/- 1.5; p = 0.02). There were no differences 
      between the groups with respect to technical success of PCA (p = 0.46), local 
      tumor control (p = 0.3), or mean number of procedures to achieve local tumor 
      control (p = 0.85). Mean increase in serum creatinine was not significantly 
      different between the two groups (p = .63). Major AEs were similar between the 
      groups (p = 1); however, the TAE + PCA group had no major hemorrhagic AEs while 
      the PCA alone group had three (8.3%). CONCLUSION: TAE + PCA in patients with T1b 
      or T2 RCC is technically feasible without significant added detriment to renal 
      function. This combined approach may help to reduce hemorrhagic AEs but larger 
      patient cohorts are needed.
CI  - (c) 2022. The Author(s), under exclusive licence to Springer Science+Business 
      Media, LLC, part of Springer Nature.
FAU - Salei, Aliaksei
AU  - Salei A
AD  - Division of Vascular and Interventional Radiology, Department of Radiology, 
      University of Alabama at Birmingham, Birmingham, AL, USA.
FAU - Raymond, Matt
AU  - Raymond M
AD  - Heersink School of Medicine, University of Alabama at Birmingham, 619, 19Th St S, 
      NHB 623, Birmingham, AL, 35249, USA.
FAU - Savage, Cody
AU  - Savage C
AD  - Heersink School of Medicine, University of Alabama at Birmingham, 619, 19Th St S, 
      NHB 623, Birmingham, AL, 35249, USA.
FAU - Huang, Junjian
AU  - Huang J
AD  - Division of Vascular and Interventional Radiology, Department of Radiology, 
      University of Alabama at Birmingham, Birmingham, AL, USA.
FAU - Caridi, Theresa M
AU  - Caridi TM
AD  - Division of Vascular and Interventional Radiology, Department of Radiology, 
      University of Alabama at Birmingham, Birmingham, AL, USA.
FAU - Rais-Bahrami, Soroush
AU  - Rais-Bahrami S
AD  - Department of Urology, University of Alabama at Birmingham, Birmingham, AL, USA.
FAU - Gunn, Andrew J
AU  - Gunn AJ
AUID- ORCID: 0000-0001-9081-446X
AD  - Heersink School of Medicine, University of Alabama at Birmingham, 619, 19Th St S, 
      NHB 623, Birmingham, AL, 35249, USA. agunn@uabmc.edu.
LA  - eng
PT  - Journal Article
DEP - 20221201
PL  - United States
TA  - Abdom Radiol (NY)
JT  - Abdominal radiology (New York)
JID - 101674571
SB  - IM
MH  - Adult
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Aged
MH  - Aged, 80 and over
MH  - Female
MH  - *Carcinoma, Renal Cell/diagnostic imaging/surgery
MH  - *Kidney Neoplasms/diagnostic imaging/surgery
MH  - Retrospective Studies
MH  - *Cryosurgery/methods
MH  - Treatment Outcome
MH  - Tomography, X-Ray Computed
OTO - NOTNLM
OT  - Ablation
OT  - Adverse events
OT  - Embolization
OT  - Renal cell cancer
EDAT- 2022/12/02 06:00
MHDA- 2023/02/09 06:00
CRDT- 2022/12/01 11:14
PHST- 2022/09/10 00:00 [received]
PHST- 2022/11/24 00:00 [accepted]
PHST- 2022/11/23 00:00 [revised]
PHST- 2022/12/02 06:00 [pubmed]
PHST- 2023/02/09 06:00 [medline]
PHST- 2022/12/01 11:14 [entrez]
AID - 10.1007/s00261-022-03755-3 [pii]
AID - 10.1007/s00261-022-03755-3 [doi]
PST - ppublish
SO  - Abdom Radiol (NY). 2023 Feb;48(2):773-779. doi: 10.1007/s00261-022-03755-3. Epub 
      2022 Dec 1.